Therefore, it is important that our results are verified ina broader and more diverse patient population. However,it is possible that NASH patients with advanced fibrosisand significant comorbidities would have even lowerPRO scores; the impact of cirrhosis to PROs may also bedifferent, ie, exacerbated or masked, in the presence ofother conditions. In addition, the use of a number ofPROs could theoretically increase the risk of gettingfalse-positive findings, although we believe that this isunlikely because of the consistency of reported trendsacross multiple outcomes as observed in our study.Finally, at present, we do not have longitudinal data thatwould link progression or regression of NASH andfibrosis to changes in PRO scores. In this context, it isimportant to note that a preliminary report from a phase2 study of the same drug suggested superior PRO scoresin patients who had their fibrosis improved37; becausethe present phase 3 studies are still ongoing, therespective on-treatment and post-treatment PRO datawith reference to the disease dynamics will be reportedin the future